Bulletin
Investor Alert

Vertex Pharmaceuticals Inc.

NAS: VRTX

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 25, 2020, 7:56 p.m.

/zigman2/quotes/202259802/composite

$

267.00

Change

-1.18 -0.44%

Volume

Volume 87,809

Quotes are delayed by 20 min

/zigman2/quotes/202259802/composite

Previous close

$ 263.13

$ 268.18

Change

+5.05 +1.92%

Day low

Day high

$260.52

$268.91

Open

52 week low

52 week high

$165.23

$306.08

Open

Company Description

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including vira...

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Valuation

P/E Current

59.40

P/E Ratio (with extraordinary items)

33.95

P/E Ratio (without extraordinary items)

48.50

Price to Sales Ratio

13.82

Price to Book Ratio

9.32

Price to Cash Flow Ratio

36.37

Enterprise Value to EBITDA

42.18

Enterprise Value to Sales

13.06

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

1,376,758.00

Income Per Employee

392,270.00

Receivables Turnover

7.88

Total Asset Turnover

0.57

Liquidity

Current Ratio

3.61

Quick Ratio

3.49

Cash Ratio

2.86

Profitability

Gross Margin

86.74

Operating Margin

28.31

Pretax Margin

33.77

Net Margin

28.49

Return on Assets

16.16

Return on Equity

22.37

Return on Total Capital

19.85

Return on Invested Capital

20.07

Capital Structure

Total Debt to Total Equity

11.06

Total Debt to Total Capital

9.96

Total Debt to Total Assets

8.09

Long-Term Debt to Equity

10.24

Long-Term Debt to Total Capital

9.22

Officers and Executives

Name Age Officer Since Title
Dr. Jeffrey M. Leiden 63 2009 Chief Executive Officer-Designee & Director
Dr. Reshma Kewalramani 46 2017 Director, Chief Medical Officer & Executive VP
Mr. Charles F. Wagner 50 2019 Chief Financial Officer & Executive Vice President
Dr. Carmen Bozic - 2019 EVP-Global Medicines Development & Medical Affairs
Mr. Mike Tirozzi - 2019 Senior VP, Chief Information & Data Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/25/2020 Margaret G. McGlynn
Director
3,707   Gift at $0 per share. 0
08/06/2020 David Matthew Altshuler
EVP, Global Research and CSO
310   Disposition at $272.6 per share. 84,506
08/06/2020 David Matthew Altshuler
EVP, Global Research and CSO
423   Disposition at $271.39 per share. 114,797
08/06/2020 David Matthew Altshuler
EVP, Global Research and CSO
490   Disposition at $270.12 per share. 132,358
08/06/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
311   Disposition at $272.53 per share. 84,756
08/06/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
422   Disposition at $271.45 per share. 114,551
08/06/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
490   Disposition at $270.13 per share. 132,363
08/06/2020 Reshma Kewalramani
CEO & President; Director
93   Disposition at $273.27 per share. 25,414
08/06/2020 Reshma Kewalramani
CEO & President; Director
487   Disposition at $272.76 per share. 132,834
08/06/2020 Reshma Kewalramani
CEO & President; Director
471   Disposition at $271.42 per share. 127,838
08/06/2020 Reshma Kewalramani
CEO & President; Director
870   Disposition at $270.36 per share. 235,213
08/06/2020 Reshma Kewalramani
CEO & President; Director
152   Disposition at $269.11 per share. 40,904
08/06/2020 Paul M. Silva
SVP & Controller
74   Disposition at $272.87 per share. 20,192
08/06/2020 Paul M. Silva
SVP & Controller
373   Disposition at $272.15 per share. 101,511
08/06/2020 Paul M. Silva
SVP & Controller
211   Disposition at $270.92 per share. 57,164
08/06/2020 Paul M. Silva
SVP & Controller
420   Disposition at $270.12 per share. 113,450
08/06/2020 David Matthew Altshuler
EVP, Global Research and CSO
1,223   Derivative/Non-derivative trans. at $155.57 per share. 190,262
08/06/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
1,223   Derivative/Non-derivative trans. at $155.57 per share. 190,262
08/06/2020 Reshma Kewalramani
CEO & President; Director
509   Derivative/Non-derivative trans. at $155.57 per share. 79,185
08/06/2020 Reshma Kewalramani
CEO & President; Director
1,564   Derivative/Non-derivative trans. at $187.53 per share. 293,296
08/06/2020 Paul M. Silva
SVP & Controller
612   Derivative/Non-derivative trans. at $155.57 per share. 95,208
08/06/2020 Paul M. Silva
SVP & Controller
466   Derivative/Non-derivative trans. at $187.53 per share. 87,388
08/03/2020 Amit K. Sachdev
EVP, Chief Patient Officer
751   Disposition at $279.18 per share. 209,664
08/03/2020 Amit K. Sachdev
EVP, Chief Patient Officer
690   Disposition at $278.25 per share. 191,992
08/03/2020 Amit K. Sachdev
EVP, Chief Patient Officer
500   Disposition at $276.96 per share. 138,480
08/03/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
280   Disposition at $279.58 per share. 78,282
08/03/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
689   Disposition at $278.72 per share. 192,038
08/03/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
413   Disposition at $277.85 per share. 114,752
08/03/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
171   Disposition at $276.4 per share. 47,264
08/03/2020 David Matthew Altshuler
EVP, Global Research and CSO
100   Disposition at $279.98 per share. 27,998
08/03/2020 David Matthew Altshuler
EVP, Global Research and CSO
605   Disposition at $279.19 per share. 168,909
08/03/2020 David Matthew Altshuler
EVP, Global Research and CSO
1,167   Disposition at $278.14 per share. 324,589
08/03/2020 David Matthew Altshuler
EVP, Global Research and CSO
458   Disposition at $276.84 per share. 126,792
08/03/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
730   Disposition at $279.41 per share. 203,969
08/03/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
1,100   Disposition at $278.13 per share. 305,943
08/03/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
500   Disposition at $276.98 per share. 138,490
08/03/2020 Paul M. Silva
SVP & Controller
19   Disposition at $279.61 per share. 5,312
08/03/2020 Paul M. Silva
SVP & Controller
429   Disposition at $278.92 per share. 119,656
08/03/2020 Paul M. Silva
SVP & Controller
310   Disposition at $277.73 per share. 86,096
08/03/2020 Paul M. Silva
SVP & Controller
51   Disposition at $276 per share. 14,076
08/03/2020 Amit K. Sachdev
EVP, Chief Patient Officer
1,941   Derivative/Non-derivative trans. at $86.52 per share. 167,935
08/03/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
1,553   Derivative/Non-derivative trans. at $86.52 per share. 134,365
08/03/2020 David Matthew Altshuler
EVP, Global Research and CSO
2,330   Derivative/Non-derivative trans. at $86.52 per share. 201,591
08/03/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
2,330   Derivative/Non-derivative trans. at $86.52 per share. 201,591
08/03/2020 Paul M. Silva
SVP & Controller
809   Derivative/Non-derivative trans. at $86.52 per share. 69,994
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
100   Disposition at $296.48 per share. 29,648
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
300   Disposition at $295.38 per share. 88,614
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
800   Disposition at $294.57 per share. 235,656
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
200   Disposition at $292.76 per share. 58,552
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
100   Disposition at $290.65 per share. 29,065
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
200   Disposition at $288.57 per share. 57,714
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
100   Disposition at $286.57 per share. 28,657
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
225   Disposition at $285.67 per share. 64,275
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
100   Disposition at $284.28 per share. 28,428
07/13/2020 Paul M. Silva
SVP & Controller
100   Disposition at $295.78 per share. 29,578
07/13/2020 Paul M. Silva
SVP & Controller
250   Disposition at $294.99 per share. 73,747
07/13/2020 Paul M. Silva
SVP & Controller
200   Disposition at $294.18 per share. 58,836
07/13/2020 Paul M. Silva
SVP & Controller
50   Disposition at $291.97 per share. 14,598
07/13/2020 Paul M. Silva
SVP & Controller
100   Disposition at $287.86 per share. 28,786
07/13/2020 Paul M. Silva
SVP & Controller
60   Disposition at $285.71 per share. 17,142
07/13/2020 Paul M. Silva
SVP & Controller
100   Disposition at $284.56 per share. 28,456
07/13/2020 Michael J. Parini
EVP, Chief Adm, Leg & BD Off
2,125   Derivative/Non-derivative trans. at $90.29 per share. 191,866
07/13/2020 Paul M. Silva
SVP & Controller
860   Derivative/Non-derivative trans. at $90.29 per share. 77,649
07/10/2020 Charles F. Wagner
EVP & Chief Financial Officer
260   Disposition at $293.9 per share. 76,414
07/10/2020 Charles F. Wagner
EVP & Chief Financial Officer
400   Disposition at $292.86 per share. 117,144
07/10/2020 Charles F. Wagner
EVP & Chief Financial Officer
40   Disposition at $291.19 per share. 11,647
07/07/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
2,786   Disposition at $300 per share. 835,800
07/07/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
1,222   Derivative/Non-derivative trans. at $155.57 per share. 190,106
07/07/2020 Stuart A. Arbuckle
EVP, Chief Commercial Officer
1,564   Derivative/Non-derivative trans. at $187.53 per share. 293,296
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
200   Disposition at $291.34 per share. 58,268
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
2,534   Disposition at $290.51 per share. 736,152
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
500   Disposition at $289.39 per share. 144,695
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
1,318   Disposition at $287.91 per share. 379,465
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
4,885   Disposition at $287.23 per share. 1,403,118
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
8,321   Disposition at $286.13 per share. 2,380,887
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
9,233   Disposition at $285.11 per share. 2,632,420
06/30/2020 Jeffrey M. Leiden
Executive Chairman; Director
5,801   Disposition at $284.14 per share. 1,648,296
06/03/2020 Diana L. McKenzie
Director
1,435   Award at $0 per share. 0
06/02/2020 Sangeeta N. Bhatia
Director
50   Disposition at $285.73 per share. 14,286
06/02/2020 Sangeeta N. Bhatia
Director
50   Disposition at $284.62 per share. 14,231
06/02/2020 Sangeeta N. Bhatia
Director
289   Disposition at $283.84 per share. 82,029
06/02/2020 Sangeeta N. Bhatia
Director
313   Disposition at $282.86 per share. 88,535
06/02/2020 Sangeeta N. Bhatia
Director
200   Disposition at $281.2 per share. 56,240
06/02/2020 Sangeeta N. Bhatia
Director
50   Disposition at $279.52 per share. 13,976
06/01/2020 Alan M. Garber
Director
699   Award at $0 per share. 0
06/01/2020 Sangeeta N. Bhatia
Director
1,398   Award at $0 per share. 0
06/01/2020 Lloyd A. Carney
Director
1,398   Award at $0 per share. 0
06/01/2020 Margaret G. McGlynn
Director
699   Award at $0 per share. 0
/news/latest/company/us/vrtx

MarketWatch News on VRTX

  1. Big Tech Weighs Too Heavily? Feast on These Stocks Instead.

    12:00 p.m. Sept. 20, 2020

    - Barron's Online

  2. Why One Analyst Thinks That Dell Is Undervalued

    9:32 p.m. Sept. 18, 2020

    - Barron's Online

  3. Moderna Shares the Latest on its Vaccine Trial

    1:19 p.m. Sept. 18, 2020

    - Barron's Online

  4. This Year’s Winning Strategy in Stock Investing: Follow the Crowd

    1:54 p.m. Sept. 16, 2020

    - Barron's Online

  5. These Companies Are Seeking a Cure for Sickle Cell

    11:53 a.m. July 25, 2020

    - Barron's Online

  6. Vertex Pharmaceuticals stock price target raised to $305 from $281 at J.P. Morgan

    7:45 a.m. July 21, 2020

    - Tomi Kilgore

  7. Here are the major brands that have pulled ads from Facebook

    12:57 p.m. July 17, 2020

    - Jon Swartz

  8. CRISPR Therapeutics Is a Top Pick for Piper Sandler. Here’s Why.

    1:04 p.m. June 29, 2020

    - Barron's Online

  9. Vertex Pharmaceuticals stock price target raised to $330 from $285 at SunTrust RH

    7:42 a.m. June 24, 2020

    - Tomi Kilgore

  10. Bluebird and Crispr Show Promise for Sickle-Cell Cures

    6:30 a.m. June 16, 2020

    - Barron's Online

  11. Biotech ETFs Are Soaring. These Four Are Still Worth Considering.

    11:46 a.m. June 2, 2020

    - Barron's Online

  12. 12 Winning Stocks This Year That Can Keep on Growing

    11:49 a.m. April 13, 2020

    - Barron's Online

  13. Active Managers Have Disappointed. But We Found Some Good Ones.

    3:17 p.m. April 10, 2020

    - Barron's Online

  14. Loading more headlines...
/news/nonmarketwatch/company/us/vrtx

Other News on VRTX

  1. Biotech Short Sellers Hike Their Bets

    9:05 a.m. Sept. 25, 2020

    - 247WallSt.com

  2. CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

    11:03 a.m. Sept. 23, 2020

    - Zacks.com

  3. How To Avoid The Noise And Invest For Long-Term Success

    12:16 p.m. Sept. 21, 2020

    - Seeking Alpha

  4. Crispr: The Frontier Of Gene Editing

    12:45 p.m. Sept. 18, 2020

    - Seeking Alpha

  5. 4 Biotech Stocks to Buy for Big Gains in 2020

    11:34 a.m. Sept. 18, 2020

    - InvestorPlace.com

  6. European advisory group backs expanded use of Vertex's Kalydeco

    8:38 a.m. Sept. 18, 2020

    - Seeking Alpha

  7. Wall Street Breakfast: Fed Reaction

    6:56 a.m. Sept. 17, 2020

    - Seeking Alpha

  8. Moderna expands cystic fibrosis partnership with Vertex Pharma

    4:48 p.m. Sept. 16, 2020

    - Seeking Alpha

  9. 3 Nasdaq Stocks to Buy Off Their Corrective Bottoms

    4:33 p.m. Sept. 16, 2020

    - InvestorPlace.com

  10. Short Sellers Hike Their Bets in Major Biotechs

    9:22 a.m. Sept. 11, 2020

    - 247WallSt.com

  11. Loading more headlines...

At a Glance

Vertex Pharmaceuticals, Inc.

50 Northern Avenue

Boston, Massachusetts 02210

Phone

1 6173416100

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$4.13B

Net Income

$1.18B

2019 Sales Growth

35.5%

Employees

3,000

/news/pressrelease/company/us/vrtx

Press Releases on VRTX

  1. Top Biotech Stocks To Watch Before Friday; 3 Names To Know

    11:48 a.m. Sept. 24, 2020

    - StockMarket.com

  2. Loading more headlines...
Link to MarketWatch's Slice.